Compare CDLR & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDLR | ANIP |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2023 | 1999 |
| Metric | CDLR | ANIP |
|---|---|---|
| Price | $25.84 | $78.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 91.3K | ★ 314.5K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $51.71 | $21.01 |
| Revenue Next Year | $34.41 | $17.59 |
| P/E Ratio | ★ $7.39 | $23.63 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $15.37 | $56.71 |
| 52 Week High | $26.79 | $99.50 |
| Indicator | CDLR | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | 55.79 |
| Support Level | $19.57 | $75.20 |
| Resistance Level | $26.79 | $85.12 |
| Average True Range (ATR) | 0.67 | 2.63 |
| MACD | 0.33 | 0.73 |
| Stochastic Oscillator | 91.78 | 60.60 |
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.